ABeta as Antiangiogenic drug

Share this postShare on Google+Share on LinkedInShare on FacebookTweet about this on TwitterEmail this to someone

Roskamp Institute has previously worked extensively on the ability of amyloid (the main protein that causes Alzheimer’s disease) to stop the growth of blood vessels. Although this is bad news in Alzheimer’s and probably contributes to the decline in cognitive function the effect has been turned to good use in other areas. The Roskamp Institute researchers have shown that amyloid or small fragments of it can stop the growth of blood vessels that supply cancers. It has been known for many years that stopping the growth of blood vessels to cancers can literally starve them of nutrients and arrest their growth or even cause them to shrink. The Roskamp Institute researchers have shown that many cancers are susceptible to having their blood supply cut off. For instance they have shown that amyloid or fragments of it can stop the growth of melanoma, lung cancer and brain tumors. Most recently they have received funding to continue their work with amyloid on lung cancers. They are interested to know whether in addition to stopping the growth of lung cancers amyloid can stop the spread of metastases which so commonly accompany this type of cancer.
Funding from the James & Esther King Biomedical Research Program grant for your project titled will help fund the work for a year and specifically will help to find smaller versions of amyloid that might be suitable for use in humans. One of the challenges that the researchers face is stopping the quick breakdown of amyloid which happens with so many proteins in the blood stream. They plan to alter the basic chemical structure of amyloid to stop it degrading.
The researchers say there is no chance that injecting amyloid can cause Alzheimer’s as it is known in fact that injecting amyloid can be used as a treatment for Alzheimer’s rather than a cause of it.
The award was based on the scientific merit assigned to the proposal by qualified peer reviewers and other factors considered by the Biomedical Research Advisory Council of the State of Florida.